EUS-FNA for Pancreatic Neuroendocrine Tumors: A Tertiary Cancer Center Experience

Atiq, Muslim; Bhutani, Manoop S.; Bektaş, Mehmet; Lee, Jeffrey E.; Gong, Yun; Tamm, Eric P.; Shah, Chintan; Ross, William A.; Yao, James C.; Raju, Gottumukkala S.; Wang, Xuemei

doi:10.1007/s10620-011-1912-7

Cited by 82 publications

(52 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We saw similar results in our series, with 23 out of 25 cases being found to be nonfunctional Pan NETs. Atiq et al [2] have reported that tumor size is directly related to the stage of disease, with tumors >2 cm in size being associated with advanced stage and metastasis. In our study, 5 patients presented with advanced-stage disease.…”

Section: Discussionmentioning

confidence: 99%

“…Pancreatic neuroendocrine tumors (Pan NETs) are rare, accounting for 1-2% of all pancreatic neoplasms [1,2]. Pan NETs, which were formerly known as islet cell tumors, are thought to arise from totipotential stem cells and neuroendocrine cells [3].…”

Section: Introductionmentioning

confidence: 99%

“…They can also present as part of the syndrome of multiple endocrine neoplasia (MEN), specifically MEN-I [1]. Traditionally, it was felt that most Pan NETs were functional, but recently it has been recognized that nonfunctional tumors are more common, with an incidence of up to 85% in some studies [2,5,6]. …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Fine-Needle Aspiration Cytology in the Diagnosis of Pancreatic Neuroendocrine Tumors: A Single-Center Experience of 25 Cases

Jahan

Yusuf²,

Loya³

2015

Acta Cytologica

View full text Add to dashboard Cite

Objective: Pancreatic neuroendocrine tumors (Pan NETs) are rare but are being increasingly diagnosed. The objective of this retrospective study was to share our experience of fine-needle aspiration (FNA), including endoscopic ultrasound-guided FNA with rapid on-site evaluation (ROSE), with the use of immunohistochemical (IHC) markers in the diagnosis of Pan NET. Study Design: A total of 25 cases of Pan NET diagnosed on pancreatic FNA between 2008 and 2013 were identified from our hospital database. Clinical history, radiology, cytomorphological features, and IHC performed were reviewed. Results: The mean age of our patient group was 52 years; 15/25 were male. Most presented with abdominal pain and the majority of the lesions were in the pancreatic body, the largest being 14 cm in size. Based on the 2010 World Health Organization criteria, cases were further graded as follows: 21 cases were grade 1, 2 cases were grade 2 and 2 cases were grade 3. Proliferation marker Ki-67 was utilized in 6 cases for definitive grading. Of the 25 cases, 23 were diagnosed as nonfunctional while 2 were functional; 1 patient had MEN-1 syndrome and 1 had von Recklinghausen's syndrome. Conclusions: Our data suggests that FNA, with ROSE and IHC markers, is highly sensitive and specific for diagnosing Pan NET.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fine-Needle Aspiration Cytology in the Diagnosis of Pancreatic Neuroendocrine Tumors: A Single-Center Experience of 25 Cases

Jahan

Yusuf²,

Loya³

2015

Acta Cytologica

View full text Add to dashboard Cite

show abstract

“…EUS can be combined with FNA to obtain cytology for NET confirmation and is safe. An earlier study in patients with pNETs, complications due to EUS+ FNA occurred in 1% (44). Moreover, in a pooled analysis of data from 19 EUS centers in the United States, the incidence of pancreatitis after EUS+ FNA of solid pancreatic lesions masses was 0.3% (45).…”

mentioning

confidence: 88%

Potential value of EUS in pancreatic surveillance of VHL patients

Asselt

Brouwers

Dullemen

et al. 2016

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Not only do EUS techniques benefit from a good sensitivity and high specificity, respectively, 82 and 92 %, but they also allow for tissue biopsy and offer the possibility of lesion tattooing [38,39]. The latter has been shown to be an invaluable advantage especially in the presence of small pNETS when a laparoscopic approach is planned [40].…”

Section: Tumor Localizationmentioning

confidence: 99%

Pancreatic Neuroendocrine Tumors: an Update

2015

View full text Add to dashboard Cite

Pancreatic neuroendocrine tumors (pNETs) are rare and comprise only 1-2 % of all pancreatic neoplastic disease. Although the majority of these tumors are sporadic (90 %), pNETs can arise in the setting of several different hereditary genetic syndromes, most commonly multiple endocrine neoplasia type 1 (MEN1). The presentation of pNETs varies widely, with over 60 % having malignant distant disease at the time of initial diagnosis involving the liver or other distant sites. Functioning pNETs represent approximately 10 % of all pNETs, secrete a variety of peptide hormones, and are responsible for several clinical syndromes caused by profound hormonal derangement. Surgery remains the cornerstone of therapy and the only curative approach. It should be pursued for localized disease and for metastatic lesions amenable to resection. Multimodality therapies, including liver-directed therapies and medical therapy, are gaining increasing favor in the treatment of advanced pNETs. Their utility is multifold and spans from ameliorating symptoms of hormonal excess (functional pNETs) to controlling the local and systemic disease burden (non-functional pNETs). The recent introduction of target molecular therapy has promising results especially for the treatment of progressive well-differentiated G1/G2 tumor. In this review, we summarize the current knowledge and give an update on recent advancements made in the therapeutic strategies for pNETs.

show abstract

EUS-FNA for Pancreatic Neuroendocrine Tumors: A Tertiary Cancer Center Experience

Abstract: EUS-FNA is a reliable modality for further characterization of suspected lesions and for establishing a tissue diagnosis. The occurrence of complications of EUS-FNA in this setting is low. Non-functional PNET are more frequently encountered than functional PNET.

Cited by 82 publications

References 35 publications

Fine-Needle Aspiration Cytology in the Diagnosis of Pancreatic Neuroendocrine Tumors: A Single-Center Experience of 25 Cases

Fine-Needle Aspiration Cytology in the Diagnosis of Pancreatic Neuroendocrine Tumors: A Single-Center Experience of 25 Cases

Potential value of EUS in pancreatic surveillance of VHL patients

Pancreatic Neuroendocrine Tumors: an Update

Contact Info

Product

Resources

About